Navigation Links
Nonlinear Dynamics announces more details of its global partnership with PerkinElmer

Nonlinear Dynamics Ltd, a leading provider of bioinformatics solutions, today announced further details of its global OEM partnership with PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research and analytical solutions.

As detailed in a press release issued last week, PerkinElmer will distribute Nonlinear's full range of 1D, 2D and array software. However the agreement also represents the formation of an integrated partnership between the two companies, with Nonlinear now formally established as PerkinElmer's principal software partner for all proteomics applications.

Mary Lopez, Business Leader for Analytical Proteomics at PerkinElmer said, "PerkinElmer was eager to establish a single strong proteomics software and bioinformatics partner going into 2005 and beyond. In entering this collaboration with Nonlinear, we are firmly endorsing Nonlinear Dynamics as that partner. The product and corporate synergies between PerkinElmer and Nonlinear made this a natural choice to benefit our customers into the future."

She continued, "PerkinElmer is re-launching its gel imaging strategy this year with ProXPRESS, our new consumables and Nonlinear's software as the centrepieces to that strategy. Our intention is to reaffirm PerkinElmer as the first choice in gel imaging, whether it be for 1D or 2D gels, blots or any other applications."

John Spreadbury, Group Sales and Marketing Director of Nonlinear Dynamics and CEO of Nonlinear USA Inc., added, "Nonlinear has provided PerkinElmer with software for a number of years now and we are very excited by this positive assertion by PerkinElmer of Nonlinear's central role within its proteomics strategy. Together we have a number of new initiatives which we are already working on. We are confident that the extensive fruits of this relationship will continue to benefit the proteomics community for many years to come."


'"/>

Source:Nonlinear Dynamics


Page: 1

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
3. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
4. GlycoFi announces the first production of antibodies with human glycosylation in yeast
5. NHGRI announces new sequencing targets
6. CHAVI announces international search for genes affecting HIV response
7. NHGRI announces latest sequencing targets
8. MUHC announces a transplant first in Quebec
9. St. Jude announces breakthrough in eye cancer treatment
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. Researcher uncovers details of how cancer spreads
Post Your Comments:
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... In the five months since passage of the ... of research-related awards have been made, supporting important scientific ... increase in basic research funding in American history - ... scientific research and education projects, while $3.5 billion is ...
... 30, 2009) A team of 80 researchers from ... Shifting Sands: Environmental and Cultural Change in Maryland,s Coastal ... barrier islands making up Maryland,s Atlantic coastline. Published ... the history, setting, context and ecology of these waterways, ...
... from the talents of Rembrandt, Van Gogh and other ... of colors on a palette. In a similar manner, ... (NIST) have created an innovative device called the "microfluidic ... concentration across an areain a miniature chamber about the ...
Cached Biology News:'Microfluidic palette' may paint clearer picture of biological processes 2
(Date:9/30/2014)... German . , ... in a semiconductor layer. Quantum dots are small structures that ... a short laser pulse is fired at the photonic crystal, ... a change in the electromagnetic field around it. This change ... by the dot. As soon as the refractive index recovers ...
(Date:9/30/2014)... , Sept. 30, 2014 Report ... segments with highest potential revenues Do you want ... report gives you revenue predictions for those biological ... those therapies you find financial data, R&D trends, ... you get sales forecasts to 2024 at overall ...
(Date:9/30/2014)... Follow us on LinkedIn ... of cholesterol carrier or lipoprotein in the blood. Such ... levels in the body, especially along the walls of ... and other cardiovascular disorders. Cardiovascular Diseases (CVD) is the ... levels on a regular basis, to assess an individual’s ...
(Date:9/30/2014)... 30, 2014 OriginOil Inc. (OTC/QB: OOIL), ... process to clean up large quantities of water, announced ... Eckelberry reported on the launch of the company's CLEAN-FRACâ„¢ ... provided by partner STW Resources . , Immediately ... per day (bpd) and achieved a 99.8% reduction in ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
... the Largest Sales Teams Promoting a 5-ASA ... 26 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: ... a co-promotion agreement with,TAP Pharmaceutical Products Inc. ... the induction of remission in patients with,active, ...
... March 26 Thomas W. Burke, MD, Executive ... M.D. Anderson,Cancer Center, has been elected the 40th ... the organization,s 39th Annual Meeting,held March 9-12, 2008 ... undergraduate and medical degrees from Tulane,University in New ...
Cached Biology Technology:Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
... suspension array system, 100-240 V, uses multiplex ... quantitative analysis of up to 100 proteins ... The suspension array is composed of up ... which may be conjugated with a unique ...
... (HTF) system, 100-240 V, is an optional ... that automates delivery of up to 20 ... array reader. The HTF system automatically draws ... container to constantly maintain a reservoir of ...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
Biology Products: